Biosafety level

Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study

Retrieved on: 
Thursday, November 2, 2023
Ebola, Virulence, Central Africa, Headache, Rocky Mountain Laboratories, Therapy, Vomiting, Diarrhea, Maxwell, Internal bleeding, Fever, Shock, Growth, Epidemic, Fatigue, RML, Biosafety level, Death, Peptide, BSL, EVD, Disease, Vaccine

The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.

Key Points: 
  • The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.
  • Once a human is infected, Ebola virus disease can be lethal within 4-5 days.
  • Maxwell is currently developing its Claromer drug platform, which has the potential to replace almost all antibiotics, antifungals and antivirals.
  • Since the first outbreak in Africa in 1976, several outbreaks and epidemics of Ebola virus have occurred in Western and Central Africa.

NorthX Biologics, a leading Nordic development and manufacturing organisation announces acquisition of a biologics manufacturing unit from Valneva

Retrieved on: 
Monday, July 3, 2023
Vaccine, GMP, Human, DNA, CGT, ATMP, BSL, Biosafety level, Karolinska University Hospital, Protein, Acquisition, Pharmaceutical industry

MATFORS, Sweden, July 03, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a focus on advanced biologics, CGT (cell and gene therapy) and vaccines, announced today the successful acquisition of the Stockholm-based Clinical Trial Manufacturing unit from Valneva Sweden, significantly expanding capabilities.

Key Points: 
  • MATFORS, Sweden, July 03, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a focus on advanced biologics, CGT (cell and gene therapy) and vaccines, announced today the successful acquisition of the Stockholm-based Clinical Trial Manufacturing unit from Valneva Sweden, significantly expanding capabilities.
  • The acquisition includes the transfer of a multi-purpose facility, situated in the Stockholm life science cluster, close to Karolinska University Hospital.
  • In addition, 30 staff members who currently operate the facility will also join NorthX.
  • We are now able to work with ATMPs and advanced biologics, including process development and manufacture for clinical trials and commercial requirements.”

SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center

Retrieved on: 
Wednesday, February 8, 2023
Lab, Vaccine, Messenger, Infection, Pandemic, PD, BSL, Gene, SK, Health, Research, Cell, Biosafety level, Joint venture, JV, R, CGT, Pharmaceutical industry, Fine chemical

Once the establishment of the R&PD Center is completed in the first half of 2025, the headquarters and the research and development (R&D) center currently located in Pangyo will move to Songdo area.

Key Points: 
  • Once the establishment of the R&PD Center is completed in the first half of 2025, the headquarters and the research and development (R&D) center currently located in Pangyo will move to Songdo area.
  • SK bioscience aims to secure the newest technologies covering the entire process from basic research to commercial manufacturing and to ultimately create a global vaccine ecosystem to preemptively respond to new infectious diseases through the establishment.
  • To achieve the goal, SK bioscience plans to operate the 'Open Lab' in the R&PD Center to strengthen a global vaccine network.
  • SK bioscience will also secure the advanced BSL-3 (Biological Safety Level) research facilities to further strengthen its own vaccine pipeline.

Agilex Biolabs expands GLP Toxicology capacity with the commissioning of its new purpose designed testing facility

Retrieved on: 
Monday, September 26, 2022
Good laboratory practice, Therapy, Health, Safety, GLP, NCE, FDA, RNA transfection, Accreditation, Severe acute respiratory syndrome coronavirus 2, BSL, IND, NATA, Review, Industry, Toxicology, COVID, Vaccine, Laboratory, Leadership, MAD, National Association, Hospital, Biosafety level, National Association of Testing Authorities, Peptide, Pharmaceutical industry

The increased capacity empowers the renowned toxicology team to continue its track record for groundbreaking successes and scientific acumen.

Key Points: 
  • The increased capacity empowers the renowned toxicology team to continue its track record for groundbreaking successes and scientific acumen.
  • In addition, Agilex is the only toxicology study provider in Australia to accommodate CAR-T therapy programs with immunocompromised models.
  • Agilex Biolabs is Australia's largest and most technologically advanced regulated bioanalytical and toxicology laboratory.
  • Healius provides quality healthcare services that are easily accessible and cost efficient, while supporting the coordination and continuity of quality patient care.

Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

Retrieved on: 
Friday, September 16, 2022
Lyme disease, COVID-19, 1018, World, Severe acute respiratory syndrome coronavirus 2, World Health Organization, Vaccination, European Commission, Company, IDT Corporation, VLA, Vero, EU, History, Biosafety level, Technology, Vaccine, Nasdaq, IDT, Chikungunya, WHO, VLA2001, Marketing, CpG, Saint-Herblain, Euronext Paris, EMA, Infection, Kingdom

As per the commercial manufacturing services agreement signed in November 20211, IDT Biologika produced VLA2001 bulk vaccine at its Biosafety Level 3 facilities in Germany, and Valneva bought the batches that were manufactured so far by IDT.

Key Points: 
  • As per the commercial manufacturing services agreement signed in November 20211, IDT Biologika produced VLA2001 bulk vaccine at its Biosafety Level 3 facilities in Germany, and Valneva bought the batches that were manufactured so far by IDT.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.
  • IDT Biologika is an innovative biotech company with a successful history dating back 100 years.
  • In the US, the IDT Corporation has a manufacturing site for clinical test samples in Rockville, Maryland.

CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer

Retrieved on: 
Tuesday, April 19, 2022
Health, Biotechnology, CEO, Lists of diseases, MIT Sloan School of Management, MBA, Gene expression, Science, CNS, RNA, RAP, Deutsche Bank, CFO, Patient, Tissue, Growth, Oligonucleotide, Institute of Liver and Biliary Sciences, Therapy, Biochemistry, Biosafety level, Gene, Business development, Multimedia, RNA transfection, Accounting, Senior, Management, Vaccine, Biogen, Finance

CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced that it has appointed Kelly Gold as its Chief Financial Officer.

Key Points: 
  • CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced that it has appointed Kelly Gold as its Chief Financial Officer.
  • Ms. Gold, who currently serves as CAMP4s Chief Business Officer and Senior Vice President of Finance, will lead all corporate finance and financial operations and will oversee relationships with financial institutions and investors.
  • Ms. Gold joined CAMP4 in 2017 and has held roles of increasing responsibility leading the Business Development and Finance functions.
  • Prior to joining CAMP4, Ms. Gold held various roles in corporate finance and business planning at Biogen, where she provided financial leadership for the companys late-stage and marketed rare disease programs.

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures

Retrieved on: 
Thursday, March 17, 2022
Department, Research, Technology, Development, Absorption, School of Advanced Warfighting, United States Army Medical Research Institute of Infectious Diseases, Skin, Risk, Biosafety level, United States Army Medical Research and Development Command, Defense, Temperature, RVSV-ZEBOV vaccine, Inhalation, Veteran, Solubility, COVID-19, Government, Infection, Pandemic, Freezing, U.S. Department of Defense Strategy for Operating in Cyberspace, USAMRIID, Biosafety, Program, Health, Therapy, Nose, NASDAQ, Severe acute respiratory syndrome coronavirus 2, TFF, Biological warfare, GLOBE, Annual report, Military, Vaccine, FDA, Institute, Safety, CRADA, Company, Military medicine, Pharmaceutical industry, Virology

Army Medical Researchand Development Command and theU.S Army'spremier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.

Key Points: 
  • Army Medical Researchand Development Command and theU.S Army'spremier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.
  • Current medical countermeasures have become less effective in recent months as new COVID-19 variants have emerged, saidGlenn Mattes, President & Chief Executive Officer ofTFF Pharmaceuticals.
  • TFF Pharmaceuticals continues to engage with various government and defense contracting agencies to utilize its Thin Film Freezing technology platform to formulate dry powder vaccines and therapeutics for mucosal delivery.
  • TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability.

CURIS System Announces Publication of ‘Disinfection of Viruses’ Book: ‘Hybrid Hydrogen Peroxide for Viral Disinfection’ Chapter

Retrieved on: 
Thursday, January 20, 2022
Science, Biotechnology, Research, Health, Medical Devices, Infectious Diseases, Chemicals, Plastics, Manufacturing, Hydrogen, Research, Technology, GLP, Overalls, HHP, Adoption, CEO, Viral, Solution, Biosafety level, EPA, Laboratory, Awareness, Vaccine, Virus

The chapter coauthored by CURIS System's senior scientist and John R. Henneman of Kansas State University Bioresearch Institute was released to an international audience.

Key Points: 
  • The chapter coauthored by CURIS System's senior scientist and John R. Henneman of Kansas State University Bioresearch Institute was released to an international audience.
  • Contributing the chapter Hybrid Hydrogen Peroxide for Viral Disinfection enables CURIS to educate a broad audience on the effectiveness of gaseous biodecontamination.
  • Utilizing the latest in biodecontamination, Hybrid Hydrogen Peroxide (HHP) technology could offer an efficacious and safer alternative to quickly make spaces and equipment germ-free and ready for reuse.
  • This chapter provides encouragement that innovations in disinfection technology, such as the HHP system, continue to keep pace with these viral threats with fact-based, science-driven results, stated Frances Grinstead, CEO, CURIS System.

Henley Ion Announces Promising Technology Developed to Protect Against COVID-19 and Emerging Variants

Retrieved on: 
Wednesday, January 12, 2022
Medical Devices, Infectious Diseases, Health, Clinical Trials, Medical Supplies, Tulane National Primate Research Center, Patient, Technology, Research, Harvard University, LinkedIn, Yale School of Medicine, Virus, Severe acute respiratory syndrome coronavirus 2, Safety, Ion, Atmosphere, CEO, Filtration, MEP, Disease, Solution, UCSF, Tulane University, Henley's Additional Continental Regiment, PPE, History, HVAC, Time, Personal protective equipment, Infection, New Orleans metropolitan area, Biosafety, Doctor of Philosophy, Dow Corning, Multimedia, Yale school, Biosafety level, Pharmaceutical industry

The objective of our efforts at Henley Ion is to provide people with the means to protect themselves from airborne pathogens.

Key Points: 
  • The objective of our efforts at Henley Ion is to provide people with the means to protect themselves from airborne pathogens.
  • Additional evaluations are ongoing at the Tulane facility under a cooperative research agreement between Henley Ion and the university.
  • The number one mission at Henley Ion is to save lives, says Skipper Bond, CEO of Henley Ion.
  • Questions about Henley Ion, the mEP technology, or licensing matters can be directed to Mr. Skipper Bond, CEO of Henley Ion at (504) 323-8129 or [email protected].

Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001

Retrieved on: 
Monday, November 29, 2021
Royal commission, Euronext Paris, UK Government Decontamination Service, News, 2020 European Medicines Agency cyberattack, Technology, IDT Corporation, Company, Achievement, CpG, Partnership, Severe acute respiratory syndrome coronavirus 2, Biosafety level, Saint-Herblain, Vaccine, IDT, COVID-19, Vaccination, History, Nasdaq, VLA, 1018, EMA, Vero, Valneva SE, Government, European Commission, Infection, European Medicines Agency, Lyme disease, Chikungunya, Pharmaceutical industry

Saint-Herblain (France) and Dessau-Rolau (Germany), November 29, 2021 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and IDT Biologika today announced their collaboration for the production of Valnevas inactivated COVID-19 vaccine candidate VLA2001.

Key Points: 
  • Saint-Herblain (France) and Dessau-Rolau (Germany), November 29, 2021 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and IDT Biologika today announced their collaboration for the production of Valnevas inactivated COVID-19 vaccine candidate VLA2001.
  • Dr. Jrgen Betzing, Chief Executive Officer of IDT Biologika, added, This is great news for our company.
  • Valneva plans to operate a combination of external and internal production of VLA2001 and will further review its manufacturing plans based on demand.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe.